A pharmaceutical company expanded its prior recall of anti-anxiety drug clonazepam tablets due to a potential “mislabeling” about the product’s strength on its carton that could be “life-threatening,” according to an announcement published by the U.S. Food and Drug Administration (FDA).
In the notice updated Nov. 19, Endo Inc. said that the impacted products, already under recall, are Clonazepam Orally Disintegrating Tablets, USP.
